Avacta Group plc
("Avacta" or the "Group")
Investor teach-in
Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces it will be hosting an investor teach-in on 5 February 2014 where Alastair Smith, CEO, will provide an overview of the Avacta business. No new material information will be disclosed.
Matt Johnson, who recently joined Avacta from Abcam as the Head of Research & Development of Avacta's Life Sciences division, will discuss the opportunity for Affimers, Avacta's proprietary affinity reagent platform.
The event, which will include a demonstration and showcase of some of the Avacta's products, will be held from 16:30 until 19:30 in the Oriental Room at the London Capital Club, 15 Abchurch Lane, London, EC4N 7BW, followed by drinks and canapés.
For more information or to register to attend, contact Walbrook PR (contact details are below).
Enquiries:
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or avacta@walbrookpr.com |
Anna Dunphy |
Mob: 07876 741 001 |
Lianne Cawthorne |
Mob: 07584 391 303 |
About Avacta Group plc - www.avacta.com
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:
Avacta Analytical
|
High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development. |
Avacta Animal Health
|
Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod. |
Avacta Life Sciences
|
Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development. |
Avacta joined AIM in August 2006 and is based in Wetherby, England.